FDA Grants Priority Review for Ifinatamab Deruxtecan in Lung Cancer

New antibody drug conjugate could offer first-in-class treatment option for previously treated patients.

Apr. 13, 2026 at 3:53pm

Got story updates? Submit your updates here. ›

A translucent X-ray photograph revealing the intricate structure of a human lung, with glowing neon lines highlighting the B7-H3 protein receptors that the ifinatamab deruxtecan therapy is designed to target.A new targeted antibody drug aims to disrupt the B7-H3 protein pathway in lung cancer cells, offering hope for patients with limited treatment options.Basking Ridge Today

The U.S. Food and Drug Administration (FDA) has granted Priority Review for ifinatamab deruxtecan, a first-in-class B7-H3 directed antibody drug conjugate, for the treatment of adult patients with previously treated extensive-stage small cell lung cancer. The decision is based on positive results from the IDeate-Lung01 phase 2 trial, with additional support from the IDeate-PanTumor01 phase 1/2 trial.

Why it matters

Small cell lung cancer is an aggressive form of lung cancer with limited treatment options, especially for patients who have already undergone prior therapy. The Priority Review designation from the FDA indicates the potential for ifinatamab deruxtecan to provide a new and innovative treatment approach for this patient population with high unmet medical need.

The details

Ifinatamab deruxtecan is a B7-H3 directed antibody drug conjugate that combines a monoclonal antibody with a topoisomerase inhibitor payload. The drug is designed to target B7-H3, a protein expressed on the surface of many solid tumor types, including small cell lung cancer. If approved, ifinatamab deruxtecan would be the first B7-H3 directed therapy available for the treatment of extensive-stage small cell lung cancer.

  • The FDA granted Priority Review for ifinatamab deruxtecan on April 13, 2026.
  • The IDeate-Lung01 phase 2 trial and IDeate-PanTumor01 phase 1/2 trial provided the data supporting the Priority Review application.

The players

U.S. Food and Drug Administration (FDA)

The federal agency responsible for regulating and supervising the safety of food, drugs, and other products in the United States.

Ifinatamab Deruxtecan

A first-in-class B7-H3 directed antibody drug conjugate being developed for the treatment of extensive-stage small cell lung cancer.

Got photos? Submit your photos here. ›

What’s next

The FDA is expected to make a decision on the approval of ifinatamab deruxtecan for the treatment of extensive-stage small cell lung cancer by the end of 2026.

The takeaway

The Priority Review designation for ifinatamab deruxtecan highlights the urgent need for new treatment options for patients with extensive-stage small cell lung cancer, a disease with limited effective therapies, especially for those who have already undergone prior treatment.